Comparative Study Evaluates Cancer Risk Associated with ACE Inhibitors and ARBs
Concerns regarding the long-term carcinogenic potential of renin–angiotensin system (RAS) inhibitors have generated considerable debate over the past decade. To better clarify this association, a comparative analysis published in PLOS ONE evaluated the relationship between angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) and the risk of developing cancer. Using a large real-world population dataset, the investigators compared cancer incidence among patients receiving ACEIs or ARBs while adjusting for relevant demographic and clinical confounding factors.
FDA Approves JIDEYTRO® (Zidesamtinib) for Previously Treated ROS1-Positive Advanced NSCLC
The US Food and Drug Administration (FDA) has approved GSK’s JIDEYTRO® (zidesamtinib) for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) whose disease has progressed following prior ROS1 tyrosine kinase inhibitor (TKI) therapy or platinum-based chemotherapy. The approval introduces a next-generation, highly selective ROS1 inhibitor designed to overcome resistance mechanisms associated with earlier-generation ROS1-targeted therapies while maintaining robust central nervous system (CNS) penetration.
Pfizer’s TALZENNA–XTANDI Combination Receives FDA Priority Review Following Positive TALAPRO-3 Results
Pfizer has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review its supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) for the treatment of adults with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations. Priority Review designation shortens the FDA review timeline for therapies that may provide significant improvements in the treatment of serious diseases, underscoring the potential clinical importance of this combination in an area of unmet need.
Prof GIUSEPPE MANCIA
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 1
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 2
Professor Dame Anna Dominiczak at ESH 2019 Milan
